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ABSTRACT - Purpose: To determine experimentally the intestinal permeability of the anticancer prodrug 
irinotecan, and to quantify the amount of its cytotoxic metabolite SN-38 that is intestinally excreted 
(exsorbed) as a predictor of intestinal toxicity, and to assess the effect of p-glycoprotein (p-gp) inhibitors 
(verapamil as a model) on the permeability and toxicity of irinotecan. Methods: Single pass intestinal 
perfusion of rat’s whole length small intestines is applied to assess the permeability of the parent drug and 
quantify the intestinally excreted metabolite. The perfusion solution contained 30μg/ml of irinotecan (control 
group) without or with verapamil (verapamil group). A simple reversed phase HPLC method with UV 
detection is developed and validated for simultaneous determination of irinotecan and SN-38 using 
camptothecin as an internal standard. Results: HPLC-UV method found to be simple, specific, accurate, and 
precise. Effective permeability coefficient of irinotecan found to be 4.9±1.710-3 mm/min and was doubled 
in verapamil group (P=0.007). Average cumulative amount of SN-38 exsorbed found to be 29 ng/cm over 2 
hours perfusion time which was decreased to 15 ng/cm in verapamil group (P=0.016). Conculsions: in situ 
intestinal perfusion method was successfully applied to quantify the permeability of irinotecan and the 
exsorption of SN-38 in the same experiment, in a manner that robustly reflects real in vivo situation. P-gp 
inhibition using verapamil found to significantly enhance the intestinal permeability of irinotecan and 
potentially decrease the intestinal toxicity due to SN-38 exposure.    
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
_______________________________________________________________________________________ 
 
INTRODUCTION 
 
Irinotecan (CPT-11) is a topoisomerase I inhibitor 
widely used for treatment of colorectal cancer. It is 
an ester prodrug that is biotransformed in vivo to its 
cytotoxic metabolite SN-38 by the action of 
carboxylesterase (1, 2). SN-38 is conjugated to 
form SN-38-glucuronide to be excreted via bile to 
the intestines, where it can be hydrolyzed back to 
SN-38 by the action of enterobacterial 
B-glucuronidase (3, 4); Figure 1 shows the 
chemical structures of irinotecan and SN-38. 
Systemic CPT-11 and SN-38 undergo excretion 
to the gut (exsorption) by the action of drug efflux 
transporters like P-glycoprotein (P-gp) (5). Both 
CPT-11 and SN-38 exist in pH dependent 
equilibrium between their lactone form 
(pharmacologically active form) in acidic media 
and open ring carboxylate form in alkaline media 
(6). Drug induced intestinal toxicity manifested as 
severe diarrhea is a main side effect of irinotecan 
found to hinder its clinical benefits (3). The 
intestinal toxic effect of irinotecan was shown to be 
associated with the intestinal exposure to the active 
metabolite SN-38 either by biliary excretion of 
SN-38 glucuronide or by intestinal excretion (3, 4).    
Drug efflux transporters mainly (p-gp) play a major 
role in the disposition of both CPT-11 and SN-38 
(7), thus, inhibition of those intestinal efflux pumps 
would be a rational way to improve oral 
bioavailability and ameliorate intestinal toxicity of 
irinotecan, due to the potential of these inhibitors 
such as verapamil to inhibit the exsorption of both 
irinotecan and SN-38 to the lumen of the gut (5). 
The oral route of irinotecan administration has been 
the subject of extensive research recently due to the 
promising results for overcoming the poor and 
erratic oral bioavailability by the action of drug 
efflux transport inhibitors (8, 9). 
In situ intestinal perfusion in rats also known as 
single pass intestinal perfusion is a commonly used  
 
 
_________________________________________ 
Corresponding Author: Gao Li; E-mail address: 
ligaotj@163.com 
J Pharm Pharmaceut Sci (www.cspsCanada.org) 14(2) 138 - 147, 2011 
 
 
 
139 
 
 
Figure 1. Chemical structures of irinotecan (CPT-11) and its active metabolite SN-38. 
 
technique for assessment of permeability of drugs 
through intestines while keeping intact blood 
supply to the intestinal tract throughout the 
experiment, making it a robust tool for simulating 
real in vivo conditions following oral drug 
administration (10-13). The improved form of this 
technique, where the whole small intestines is used 
for more accurate determination of drug’s 
permeability, especially for low permeability 
compounds, has been recently introduced in our lab 
and published elsewhere (14). 
HPLC methods for determination of both 
CPT-11 and SN-38 in biological fluids have already 
been described. Many of them required complicated 
and expensive equipments such as LC-MS or 
fluorescence detectors with the capability of 
switching wavelength (15-17]). UV detection is 
considered to be simple and most accessible for the 
research community. A recently reported gradient 
elution HPLC-UV analysis method for CPT-11 and 
SN-38 required a relatively long run time of 35 min 
(18).      
In this report we are designing an in situ 
experiment for assessing both permeability and 
intestinal toxicity of irinotecan utilizing the 
improved in situ intestinal perfusion model and 
applying this model to study the potential effect of 
efflux transport inhibitors on the absorption and 
intestinal toxicity of irinotecan. To achieve this goal 
we developed and validated a new, simple, and 
rapid isocratic reversed phase HPLC-UV method 
for simultaneous determination of CPT-11 and 
SN-38 in the lumen of rat’s small intestines 
following in situ intestinal perfusion of irinotecan. 
And to assess the effect of efflux transporter 
inhibition on the permeability and toxicity of 
irinotecan the widely used p-gp inhibitor verapamil 
was used as a model p-gp inhibitor.  
To our best knowledge there is no available 
published work that uses the in situ perfusion 
model to study the permeability and intestinal 
toxicity of irinotecan.  
 
METHODS 
 
Materials 
Irinotecan hydrochloride was a gift from Jiang Su 
Heng Rui Medicine Co. Ltd. (China). SN-38 and 
camptothecin were purchased from Cheng Du 
Lanbei Phytochemistry Science and Technology Co. 
Ltd. (china).Verapamil hydrochloride was obtained 
from Centralpharm Inc. (china). DMSO and 
acetonitrile obtained from Sinopharm Chemical 
Reagent Co. Ltd. (china). All other chemicals and 
reagents were of HPLC or analytical reagent grade.    
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Instruments and Chromatographic Conditions 
For chromatographic analysis a Hitachi HPLC 
System (Kyoto, Japan) was used, which was 
equipped with a quaternary gradient flow pressure 
mixing pump (L-2130), and a UV detector 
(L-2400). A  Knauer Eurospher 100-5 C18 
chromatographic column (250mm×4.0mm) was 
used for separation, with a C18 (4mm×10mm i.d., 
10μm) pre-column from Knauer (Berlin, Germany). 
The mobile phase was acetonitrile:20mM 
KH2PO4 (35:65,v:v) with final pH adjusted to 3.5 
using phosphoric acid. Prior to use, the mobile 
phase was filtered through a 0.22μm microporous 
membrane (phenomenon technology development 
Co. Ltd. (china)), and degassed by ultrasonication. 
Separations were performed at room 
temperature (25 ±2°C) and a flow rate of 
1.0mL/min, 50 μL was injected into the system for 
analysis. The wave length of UV detection was set 
at 380nm. The structurally related compound 
camptothicin (CPT) was used as an internal 
standard (IS).  
 
Preparation of Stock and Standard Solutions 
Individual stock solutions of CPT-11, SN38 and 
CPT (2 mg/mL) were prepared in DMSO, divided 
into aliquots and stored at −20°C. standard 
calibration solutions and quality control samples 
were prepared daily by diluting aliquots from the 
stock solution into blank perfusion solution 
(perfused through rat’s small intestines). Internal 
standard (IS) solution was a solution of CPT 10 
μg/ml in 6% perchloric acid.      
 
Sample Preparation 
Frozen intestinal perfusion samples were thawed at 
room temperature and 200 μL of IS solution were 
added to 200 μL of the perfusion sample and 
vortexed for 1 min then centrifuged at 12000 rpm 
for 10 min. The addition of IS solution that contain 
6% perchloric acid is enough for the conversion of 
the carboxylate forms of CPT-11 and SN-38 to their 
lactone forms, and to precipitate protein impurities 
that could be present as a result of the intestinal 
perfusion process.   
 
Animals 
Male Sprague–Dawley rats (220–280 g) were 
obtained from the Experimental Animal Supply 
Center of Tongji Medical College, Huazhong 
University of Science and Technology, Wuhan, 
China. Rats were acclimatized for one week under  
 
controlled conditions including a light/dark cycle of 
12 hours, and a temperature of 25°C. Food and 
water were provided on an ad libitum basis. All 
animal experiments were performed in strict 
accordance with the Guidelines for Animal 
Experimentation of Tongji Medical College, 
Huazhong University of Science and Technology, 
Wuhan, China. 
 
Composition of the Perfusion Solution 
The perfusion solution consisted of 10 mM 
D-glucose, 120 mM NaCl, 4.6 mM KCl, 1.5 mM 
NaH2PO4, 0.7 mM Na2HPO4, 0.5mM MgCl2, and 
15 mM NaHCO3 Per Liter of distilled water. 
Aliquots from the stock solution of irinotecan were 
added to achieve a CPT-11 concentration of 
30μg/ml and 1.5% v/v of DMSO, (Venkatesh G et 
al) demonstrated that DMSO levels of up to 5% did 
not interfere with the permeability parameters 
obtained from SPIP experiments (19). For the P-gp 
inhibition experiments 150 μg/ml of verapamil 
hydrochloride was used. The pH of the perfusion 
solution was adjusted to 6.5 using phosphoric acid. 
Preliminary experiments showed that no 
considerable adsorption of the compounds on the 
tubing and other apparatus took place. 
 
Improved In Situ Single Pass Intestinal 
Permeability  
The improved in situ perfusion studies were 
performed using established method described 
previously (14), with minor modifications. Prior to 
the surgical procedure, the rats were fasted 
overnight (16–20 h) with water ad libitum.  The 
rats were anesthetized with intraperitonial injection 
of urethane (150 mg/100g body weight) and placed 
on a heating pad to maintain normal body 
temperature (37°C).  The intestines of the rats 
were exposed by a midline abdominal incision. Bile 
duct was ligated to exclude the effect of biliary 
excretion. During surgical procedure great deal of 
care was taken so as not to interrupt blood 
circulation of the intestinal tract.  Proximal and 
distal ends of the small intestines were identified 
and canulated using silicone tubing (4mm diameter) 
for inlet and outlet perfusion respectively. Small 
intestines were covered with a wet pad throughout 
the experiment to prevent dehydration.  Normal 
saline solution (37°C) was gently pumped through 
the inlet tubing, to rinse the intestines, until the 
outlet is clear. Inlet tubing was attached to 
peristaltic pump (Petro Gas Ausrüstungen, Berlin,  
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Germany), with Perfusion solution (37°C) 
continuously pumped at a flow rate of 0.3ml/min 
for 180 min. Collection of perfusate was done 
following a pre established schedule i.e. 10 minutes 
intervals beginning after 60 minutes of continuous 
perfusion. Achievement of steady state levels of 
irinotecan in the perfusate from pilot experiments 
found to be 60-90 minutes.  At the end of the 
experiments the animal was euthanized by a single 
lethal intracardiac dose of anesthetic (urethane) and 
the length of the intestinal segment was measured. 
Net water flux (NWF) in the rat in situ experiment 
was quantified by weight and volume 
measurements (13, 14). Samples were kept frozen 
at −20°C until analyzed. 
 
DATA ANALYSIS AND STATISTICS 
 
Effective permeability coefficient (Peff) of 
Irinotecan was calculated from the steady-state 
concentrations of the compound in the perfusate 
collected after correction for NWF. Permeability 
values were calculated using the following equation 
according to the parallel tube model (20): 
 
( )
eff
ln[ / ]
P =
2
out corrected inQ C C
rl

 
 
Where Cin is the inlet concentration and Cout (corrected) 
is the outlet concentration of compound, which is 
corrected for volume change in intestines using 
weight and density measurements. Q is the flow 
rate (0.3 ml/min), r is the rat intestinal radius (0.18 
cm) (20), and l is the length of the intestines 
measured after completion of the experiment. The 
exsorbed SN-38 measured in the outlet perfusate 
was used as a potential predictor of intestinal 
toxicity of irinotecan. All values were presented as 
mean ± standard deviation of 6 different animals. 
For comparing the two groups for statistical 
significance, one way ANOVA was used. P values 
less than 0.05 considered as statistically significant. 
 
HPLC Method validation 
 
Specificity 
Specificity evaluation was carried out using five 
different blank rat perfusion samples that were 
treated the same way real experiment samples being 
treated, and injected into the HPLC to assess 
whether or not endogenous constituents might 
interfere at the retention time of both analytes 
(CPT-11 and SN-38) and internal standard (CPT). 
Figure 2 shows a representative chromatogram of a 
blank perfusion sample. 
 
 
 
Figure 2 a representative chromatogram of a blank perfusion solution that was perfused through the rat’s small 
intestines revealing the absence of interfering peaks. 
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Linearity 
Seven-point linearity curves were constructed for 
three consecutive days for each analyte. A 
correlation of more than 0.999 was obtained for 
both linearity curves. 
 
Accuracy and precision 
The accuracy of the method was established by 
using quality control samples at low, medium and 
high concentrations of 2.5, 25 and 50μg/mL for 
CPT-11 and 0.05, 0.5 and 2μg/mL for SN-38. All 
the samples were prepared in five replicates. 
Accuracy was calculated using the formula %RE = 
(E − T)(100/T) where E is the experimentally 
determined concentration and T is the theoretical 
concentration. Precision was assessed by 
calculating inter and intra-day variability of quality 
control samples at low, medium and high 
concentrations. Inter-day data was obtained by 
analyzing the quality control samples on three 
consecutive days of assay, while the intra-day 
precision data was obtained by analyzing three sets 
of quality control samples in a single day. Assay 
precision was calculated using the formula %RSD 
= (SD/M) × 100 where M is the mean of the 
experimentally determined concentrations and SD 
is the standard deviation of M. 
 
Recovery 
The percentage recovery was determined by using 
quality control samples at low, medium and high 
concentrations of 2.5, 25 and 50 μg/mL for CPT-11 
and 0.05, 0.5 and 2μg/mL for SN-38. Recovery was 
calculated by comparing the mean ratio of (peak 
area of analyte)/(peak area of internal standard) of 
five replicates (n = 5) of spiked blank perfusion 
samples to those spiked in mobile phase. 
 
Stability studies 
Stability experiments were performed with low, 
medium and high quality control samples to 
evaluate the stability of both analytes in blank 
perfusion samples under different conditions by 
simulating the same conditions that encountered 
during our experiment’s sample analysis. 
Experiments were performed to determine 
on-bench (25 ±2°C) stability (after 8 h), three 
(freeze–thaw) cycles stability and short-term 
stability at −20°C for 30 days. 
 
 
 
Lower limits of detection and quantification 
Lower limit of detection (LOD) and lower limit of 
quantification (LOQ) where approached based on 
the standard deviation of the response and the slope 
of the calibration curve according to the following 
formulae (ICH guidelines) (21): 
3.3LOD
S
  
10LOQ
S
  
Where  = the standard deviation of the response 
which was estimated as the standard deviation of 
y-intercepts of 3 calibration regression lines, and S 
= the slope of the calibration curve 
 
RESULTS 
 
Chromatographic Method 
Following a brief sample treatment step that 
resulted in protein precipitation as well as 
conversion of the open ring carboxylate form of the 
two analytes to their closed ring lactone form, good 
separations were achieved within 10 min. 
validation parameters all found to be within the 
accepted range as explained in the following 
subsections.       
 
Specificity 
The optimum single UV wavelength for detection 
of the two analytes (CPT-11 and SN-38) and the 
internal standard (CPT) simultaneously with 
adequate sensitivity was found to be 380 nm, since 
a fixed wavelength detector was used. There were 
no interfering peaks of endogenous compounds 
observed at the retention times of the two analytes 
and the internal standard in blank perfusion sample. 
Retention times found to be 3.7, 6.6, and 9.0 
minutes for CPT-11, SN-38, and CPT, respectively. 
A representative chromatogram is shown in Figure 
3. 
 
Linearity 
Samples were quantified using the concentration – 
response relationship given by the simple 
regression analysis: y = mx + c, with the response 
being the peak area of the analyte to that of the 
internal standard. The correlation coefficients of the 
calibration curves for both analytes were more than 
0.999. Linearity parameters for CPT-11 and SN-38 
are shown in Table 1. 
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Figure 3. Representative chromatogram of a sample from intestinal perfusion containing (A: 31.25ug/ml CPT-11, B: 
1.25ug/ml SN-38, C: Internal Standard camptothecin. 
 
 
 
 
Accuracy and precision 
For CPT-11 and SN-38 the intra-day accuracy was ≤7.49% and ≤7.36%, respectively, while the intra-day 
precession was ≤2.71% for CPT-11 and ≤2.98% for SN-38. The inter-day accuracy was ≤7.21% and ≤6.14% 
for CPT-11 and SN-38, respectively, while the inter-day precession was ≤1.95% and ≤3.19% for CPT-11 
and SN-38 respectively. The accuracy and precision results for both intra- and inter-day are shown in Table 
2. 
 
 
Table 2. Intra and inter-day precision expressed as %RSD and accuracy expressed as %RE obtained from three 
calibration curves with three levels of quality control samples of CPT-11 and SN-38. 
Intra-day (5 replicates) Inter-day(3 days) 
CPT-11 spiked 
concentration(μg/mL) 
Mean measured 
concentration(μg/mL) 
Standard 
deviation(μg/mL) 
%RE %RSD %RE %RSD 
2.5 
25 
2.69 0.073 7.49 2.71 7.21 1.21 
1.64 25.42 0.606 1.66 2.39 3.44 
50 
SN-38 spiked 
conccentration(μg/mL) 
50.85 0.547 1.71 1.07 3.00 1.95 
  
0.05 
0.50 
2.00 
0.0537 0.0016 7.36 2.98 6.14 3.19 
3.01 0.5130 0.0065 2.61 1.27 4.43 
2.0766 0.0197 3.83 0.94 4.23 1.99 
Table 1. Linearity parameters of CPT-11 and SN-38 expressed as mean (standard deviation) of three calibration curves 
Analyte Range(μg/mL) Slope Intercept Correlation coefficient 
CPT-11 
SN-38 
(0.98-62.5) 0.0626 (0.0015) 0.01147 (0.0077) 0.9997 (0.0002) 
(0.04-2.5) 0.1786 (0.0139) 0.0005 (0.0001) 0.9996 (0.0002) 
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Recovery 
The percentage recovery for CPT-11 was 106.2%, 
100.8%, and 101.2%, for low, medium, and high 
quality control concentrations, respectively. For 
SN-38 the recovery of low, medium, and high 
concentrations, was 100.4%, 102.9%, and 99.7%, 
respectively. 
 
Stability  
Stability assessment for CPT-11 and SN-38 was 
carried at low, medium and high quality control 
concentrations. Both analytes were found to be 
stable in the blank perfusion sample for 8 h at room 
temperature (25 ±2°C) and after three cycles of 
freezing (at −20°C) and thawing (at room 
temperature). The samples were stored at −20°C for 
short-term stability studies and found to be stable 
for at least 30 days. Stability results are 
summarized in Table 3.  
 
Lower limits of detection and quantification 
LOD and LOQ for SN-38 calculated to be 0.0018 
and 0.0056 μg/ml respectively. Corresponding 
concentrations were spiked and analyzed practically 
to assess the validity of the calculation method, and 
found to be within the accepted range of accuracy. 
For application to our in situ experiment there was 
no need to determine concentrations of CPT-11 
lower than those used in the linearity and accuracy 
assessment, so, LOQ for CPT-11 set to be the 
lowest concentration used in this method 
validation’s linearity assessment i.e. 0.98 μg/ml.    
 
Rat’s Single Pass Intestinal Perfusion 
Applying the above mentioned validated HPLC 
method we successfully determined the level of the  
 
 
 
 
parent drug irinotecan and its active metabolite 
SN-38 following rats intestinal perfusion of 
irinotecan (control group) or irinotecan plus the 
p-glycoprotein inhibitor verapamil (verapamil 
group). The concentration of CPT-11 in the 
perfusate was used to calculate the effective 
permeability coefficient Peff of irinotecan which 
found to be 4.9±1.7  10-3 mm/min that 
corresponded to an outlet:inlet drug concentration 
of 0.88  0.03. When verapamil was coperfused 
with irinotecan Peff increased to 10.4±3.4  10-3 
mm/min (P=0.0073), Figure 4, and the outlet:inlet 
drug concentration decreased to 0.72  0.08 
(P=0.0014). 
In control group the average cumulative 
amount of SN-38 exsorbed found to be 29 ng/cm 
over 2 hours perfusion time which was decreased to 
15 ng/cm in verapamil group (P=0.016), Figure 5 
shows the cumulative exsorbed SN-38 in the two 
groups. 
 
DISCUSSION 
 
Compared to the previously described analytical 
methods for determination of CPT-11 and SN-38, 
this isocratic HPLC-UV method found to be 
advantageous in terms of simplicity and feasibility. 
HPLC-UV instruments are considered to be, for 
most researchers, more accessible and feasible than 
LC-MS, HPLC with switching wavelength 
fluorescence detectors, or even HPLC with 
conventional fluorescence detectors, which is the 
case in our lab. 
 
 
 
 
 
Table 3. Stability data of quality control samples of CPT-11 and SN-38 at different conditions expressed as %RE. 
CPT-11 spiked concentration 
(μg/mL) 
Benchtop stability 3 freeze-thaw 
cycles 
−20°C for 30 days 
2.5 
25 
-3.22 -5.18 -5.77 
-2.42 -3.44 -3.74 
50 1.53 -1.86 -3.91 
SN-38 spiked conccentration (μg/mL)    
0.05 -4.69 -5.61 -4.22 
0.50 
2.00 
-1.17 -2.48 -2.73 
2.07 -0.89 3.43 
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Figure 4. Effective permeability coefficient (Peff) of irinotecan obtained from in situ perfusion experiments in rats with 
(+verapamil) and without (Control) the P-gp inhibitor verapamil (P=0.0073), error bars represent the standard deviation 
of 6 readings each. 
 
 
 
Figure 5. The cumulative exsorbed SN-38 that resulted from perfusion of irinotecan with or without the p-gp inhibitor 
verapamil (P=0.016). Error bars represent the standard deviation of n=6. 
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Intestinal permeability for a variety of drugs 
obtained from in situ single pass intestinal 
perfusion experiments have shown excellent 
correlation with human perfusion studies (11, 22). 
Also, in situ intestinal permeability of nine drugs 
were well correlated with corresponding human 
results in terms of whether these drugs being 
actively absorbed or they are subject to simple 
passive diffusion (12). In addition, permeability 
parameters obtained from in situ intestinal 
perfusion model provided a better prediction of 
human absorption than the cell-based assays (23). 
The improved form of the intestinal perfusion 
technique, where the whole small intestine was 
used, allowed not only accurate determination of 
the permeability of the drug, but also gave 
information on the toxicity predicted due to SN-38 
intestinal exposure, since the perfusion of the drug 
along the whole small intestines can give rise to 
quantifiable amounts of the active metabolite that is 
intestinally exsorbed. 
The fact that excretion (exsorption) can give 
rise to appreciable concentration of SN-38 in the 
gut’s lumen was previously demonstrated using the 
in situ intestinal perfusion technique following 
intravenous administration (5). And since the 
intestinal exposure to SN-38 in the gut was 
associated with the development of severe toxicity 
manifested as drug induced diarrhea [3, 4], we 
suggested that quantifying the level of SN-38 that is 
exsorbed following intestinal perfusion of 
irinotecan shall be a good indicator for predicting 
irinotecan induced intestinal toxicity that results 
from drug administration. 
Although drug-drug interactions of irinotecan 
and SN-38 with verapamil have already been 
described in previous works using Caco2 cells 
model and in vivo in rats (8), applying the improved 
in situ model provided two main additions, the first, 
is that it allowed the determination of the intestinal 
permeability of the parent drug, which is, to our 
best knowledge, the first published work providing 
the Peff of irinotecan, the second, is that it allowed 
the quantification of SN-38 exposure at the site 
where toxicity takes place.      
 
CONCLUSION 
 
Our HPLC-UV analytical method for the 
determination of the prodrug irinotecan and its 
active metabolite SN-38 was validated and found to 
be simple, specific, accurate, and precise. And used  
 
to apply the improved rat’s in situ single pass 
intestinal perfusion (SPIP) technique to assess the 
permeability, and intestinal toxicity of irinotecan 
predicted to result from exsorbed SN-38. The 
effects of P-gp inhibitor verapamil were also 
successfully evaluated and found to increase the 
intestinal permeability and potentially decrease the 
intestinal toxicity encountered upon the 
administration of irinotecan. P-gp inhibitors 
interaction with irinotecan necessitates future 
efforts to evaluate their potential to improve the 
oral bioavailability and ameliorate intestinal 
toxicity of irinotecan. This method provides a 
useful tool for predicting oral absorption of 
irinotecan and the accompanying exsorbed SN-38. 
This method will be applied in our lab to assess 
the effect of different compounds for their potential 
to improve the intestinal permeability and decrease 
the toxicity of irinotecan for the purpose of 
evaluating novel oral formulations of irinotecan 
based on p-gp inhibition. 
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